Bladder cancer, part 1;Blasenkarzinom: Teil 1: Radikale Zystektomie, neoadjuvante und adjuvante Therapiemodalitaten

Urologe - Ausgabe A

Volumn 37, Issue 1, 1998, Pages 93-101

  Lampel, A ^a,c   Thuroff J W ^b  

^a HELlOS Klinikum Wuppertal   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CYSTECTOMY; HUMAN; LYMPHADENECTOMY; METASTASIS; PREOPERATIVE EVALUATION; URETHRA SURGERY;

CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; NEOPLASM INVASIVENESS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 0008960232     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050157     Document Type: Article

References (22)

1. Blandy J P, England H R, Evans S J W, Hope-Stone H F, Mair G M, Mantell B S, Oliver R T, Paris A M, Risdon R A (1980) T3 bladder cancer: the case for salvage cystectomy. Br J Urol 52:506-510
2. Fosså S D, Ous S, Tveter K, Otnes B, Igesund A, Dingsør E, Aunan O, Taksdahl S, Scott-Knudsen O, Lund E, Dingsr E (1986) Treatment of T2/T3 bladder carcinoma: total cystectomy with and without preoperative irradiation. Eur Urol 12:158-163
3. Freiha F, Reese J, Torti F (1996) Randomized trial of radical cystectomy vs radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155:495-500
4. Ghoneim M A (1997) Orthotopic bladder substitution in women following cystectomy for bladder cancer. Urol Clin North Am 24:225-239
5. Logothetis C J, Johnson D E, Chong C, Dexeus F H, Sella A, Ogden S, Smith T, Swanson D A, Babaian R J, Wishnow K I, von Eschenbach A (1988) Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer. J Clin Oncol 6:1590-1596
6. Martinez-Pineiro J A, Gonzalez Martin M, Arocena F, Flores N, Ramos Roncero C, Portillo J A, Escudero A, Jimenez Cruz F, Isorna S (1995) Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 153:964-973
7. Parsons J T, Million R R (1988) Planned preoperative irradiation in the management of clinical stage B2-C (T3) bladder carcinoma. Int J Radiat Oncol Biol Phys 14:797-810
8. Richards B, Aso Y, Bollack C, Fossa S, Koontz W, Matsuda M, Matsumoto K, Prout G, Van der Werft B, Wolf H (1986) Prognostic factors in infiltrating bladder cancer. Prog Clin Biol Res 221:271-286
9. Roehrborn C G, Sagalovsky A I, Peters P C (1991) Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma. J Urol 146:36-39
10. Rübben H, Otto T (1997) Harnblasenkarzinom. In: Rubben H (Hrsg) Uro-Onkologie. Springer, Berlin Heidelberg New York, S 85-178
11. Scher H I (1996) Editorial comment. J Urol 155:499-500
12. Scher H I, Yagoda A, Herr H W, Sternberg C N, Bosl G, Morse M J, Sogani P C, Watson R C, Dershaw D D, Reuter V, Geller N, Hollander P S, Vaughan E D J, Whitmore W F J, Fair W R (1988) Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 139:470-474
13. Schoenberg M P, Walsh P C, Breazeale D R, et al (1996) Local recurrence and survival following nerve sparing radical cystectomy for bladder cancer: 10-year followup. J Urol 155:490-494
14. Skinner D G (1982) Management of invasive bladder cancer: a meticulous pelvic lymph node dissection can make a difference. J Urol 128:34-36
15. Skinner D G, Daniels J R, Russel C A, Lieskovsky G, Boyd S D, Nochols P, Kern W, Krailo M, Groshen S (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145:459-467
16. Skinner D G, Lieskovsky G (1988) Management of invasive and high-grade bladder cancer. In: Skinner DG, Lieskovsky G (Hrsg) Diagnosis and management of genitourinarycancer. Saunders, Philadelphia, Bd. 1, S 295-312
17. Srougi M, Simon S D (1994) Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5-year followup. J Urol 151:593-597
18. Sternberg C N, Yagoda A, Scher H I, Watson R C, Geller N, Herr H W, Morse M J, Sogani P C, Vaughan E D, Bander N, Weiselberg L, Rosado K, Smart T, Lin S, Penenberg D, Fair W R, Whitmore W F J (1985) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 122:403-407
19. Stöckle M, Meyenburg W, Hohenfellner R (1991) Verbesserte Überlebensraten nach radikaler Zystektomie durch M-VAC/M-VEC adjuvant. Urologe [A] (Suppl) A73
20. Stockle M, Wellek S, Meyenburg W, Voges G E, Fischer U, Gertenbach U, Thüroff J W, Huber C, Hohenfellner R (1996) Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 48:868-875
21. Thrasher J B, Crawford E D (1993) Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 149:957-972
22. Wishnow K I, Dmochowski R (1988) Pelvic recurrence after radical cystectomy without preoperative radiation. J Urol 140:42-44